Scholar Rock Holding (SRRK) Total Liabilities (2017 - 2026)
Scholar Rock Holding (SRRK) recorded quarterly Total Liabilities of $259.2 million in Q1 2026, up 63.27% quarter-over-quarter from $158.8 million in Q4 2025, and up 172.25% on a YoY basis from $95.2 million in Q1 2025.
Scholar Rock Holding (SRRK) Total Liabilities (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Total Liabilities history runs 10 years deep, the most recent figure standing at $259.2 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 172.25% year-over-year to $259.2 million; the TTM figure through Mar 2026 stood at $259.2 million (up 172.25% YoY), while the FY2025 annual figure was $158.8 million, up 49.39% from the prior year.
- Total Liabilities was $259.2 million for Q1 2026 at Scholar Rock Holding, up from $158.8 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $259.2 million in Q1 2026 to a low of $82.4 million in Q2 2023.
- Historically, Total Liabilities has averaged $111.3 million across 5 years, with a median of $95.2 million in 2025.
- The sharpest annual moves came in 2022 and 2026: Total Liabilities declined 26.02% in 2022, then surged 172.25% in 2026.
- A 5-year view of Total Liabilities shows it stood at $97.9 million in 2022, then slipped by 12.37% to $85.8 million in 2023, then increased by 23.85% to $106.3 million in 2024, then surged by 49.39% to $158.8 million in 2025, then surged by 63.27% to $259.2 million in 2026.
- The last three Total Liabilities figures came in at $259.2 million (Q1 2026), $158.8 million (Q4 2025), and $166.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.74 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.48 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 731.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 10.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 19.51 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 943,068.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 7.12 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 137.56 Mn |
| 10 | Scholar Rock Holding | 6.03 Bn | 5.55 Bn | - | 259.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 259.24 Mn |
| Dec 31, 2025 | 158.78 Mn |
| Sep 30, 2025 | 166.72 Mn |
| Jun 30, 2025 | 106.75 Mn |
| Mar 31, 2025 | 95.22 Mn |
| Dec 31, 2024 | 106.29 Mn |
| Sep 30, 2024 | 99.94 Mn |
| Jun 30, 2024 | 93.25 Mn |
| Mar 31, 2024 | 84.51 Mn |
| Dec 31, 2023 | 85.82 Mn |
| Sep 30, 2023 | 83.02 Mn |
| Jun 30, 2023 | 82.40 Mn |
| Mar 31, 2023 | 86.07 Mn |
| Dec 31, 2022 | 97.93 Mn |
| Sep 30, 2022 | 97.04 Mn |
| Jun 30, 2022 | 94.62 Mn |
| Mar 31, 2022 | 94.66 Mn |
| Dec 31, 2021 | 132.37 Mn |
| Sep 30, 2021 | 111.13 Mn |
| Jun 30, 2021 | 115.40 Mn |